BETA — Beta Drugs Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapFalling Star

Annual income statement for Beta Drugs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,838	2,271	2,957	3,624	3,848
Cost of Revenue
Gross Profit	716	971	1,145	1,504	2,136
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,484	1,841	2,456	3,003	3,263
Operating Profit	354	430	501	621	585
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	343	411	488	615	544
Provision for Income Taxes
Net Income After Taxes	248	307	364	470	415
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	248	307	364	424	415
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	248	307	364	424	415
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	24.6	30.4	36.1	46.5	40.9